[go: up one dir, main page]

AU2003251709A1 - Diagnostic and therapeutic use of proteolipid protein for alzheimer's disease - Google Patents

Diagnostic and therapeutic use of proteolipid protein for alzheimer's disease

Info

Publication number
AU2003251709A1
AU2003251709A1 AU2003251709A AU2003251709A AU2003251709A1 AU 2003251709 A1 AU2003251709 A1 AU 2003251709A1 AU 2003251709 A AU2003251709 A AU 2003251709A AU 2003251709 A AU2003251709 A AU 2003251709A AU 2003251709 A1 AU2003251709 A1 AU 2003251709A1
Authority
AU
Australia
Prior art keywords
alzheimer
diagnostic
disease
therapeutic use
proteolipid protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003251709A
Other languages
English (en)
Inventor
Johannes Pohlner
Heinz Von Der Kammer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec Neurosciences GmbH
Original Assignee
Evotec Neurosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences GmbH filed Critical Evotec Neurosciences GmbH
Publication of AU2003251709A1 publication Critical patent/AU2003251709A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003251709A 2002-08-19 2003-08-18 Diagnostic and therapeutic use of proteolipid protein for alzheimer's disease Abandoned AU2003251709A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40413102P 2002-08-19 2002-08-19
EP02018567.4 2002-08-19
US60/404,131 2002-08-19
EP02018567 2002-08-19
PCT/EP2003/009130 WO2004019044A1 (fr) 2002-08-19 2003-08-18 Utilisation diagnostique et therapeutique de la proteine proteolipide contre la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
AU2003251709A1 true AU2003251709A1 (en) 2004-03-11

Family

ID=31947888

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003251709A Abandoned AU2003251709A1 (en) 2002-08-19 2003-08-18 Diagnostic and therapeutic use of proteolipid protein for alzheimer's disease

Country Status (2)

Country Link
AU (1) AU2003251709A1 (fr)
WO (1) WO2004019044A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0685558A1 (fr) * 1994-05-27 1995-12-06 Bayer Ag Animaux transgéniques déficients en protéine protéolipidique et méthode d'obtention de tels animaux

Also Published As

Publication number Publication date
WO2004019044A1 (fr) 2004-03-04

Similar Documents

Publication Publication Date Title
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
AU2003220096A1 (en) Methods for alzheimer's disease treatment and cognitive enhancement
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
SI1334091T1 (sl) Derivati tioflavina in njihova uporaba pri diagnozi in terapiji pri Alzheimerjevi bolezni
EP1392287B8 (fr) Usage de dérivés de l'azétidinone pour le traitement de la maladie d' Alzheimer.
AU2003277010A1 (en) A method and system for detecting the effects of alzheimer's disease in the human retina
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU2003268295A8 (en) "diagnosis and treatment of infertility"
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
AU2003303141A1 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2003248660A1 (en) Treatment of vascular dysfunction and alzheimer's disease
AU2001289834A1 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
AU2003260301A1 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
PL377110A1 (pl) Zapobieganie i leczenie choroby Alzheimera
AU2002352054A1 (en) "in vitro" diagnostic method for diseases affecting human or animal tissues
AU2003279312A1 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
AU2003288127A1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF H-Rev107 PROTEIN FOR ALZHEIMER DISEASE
AU2003251709A1 (en) Diagnostic and therapeutic use of proteolipid protein for alzheimer's disease
IL172213A0 (en) Compounds useful in the therapy of alzheimer's disease and formulations containing them
AU2003289859A1 (en) Diagnostic and therapeutic use of arl7 for alzheimer's disease
AU2003286530A1 (en) Substituted peptides useful in the treatment of alzheimer's disease
AU2002312797A1 (en) Peptide for the diagnosis and therapy of alzheimer's disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase